Ascension St. Vincent Hospital
Indianapolis, Indiana, 46260, United States
Location status: Recruiting
Location contact
Jamie Williams
CONTACT
Lewis Jacobson, MD
SUB_INVESTIGATOR
Nakul Valsangkar, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07485829
Prospective, single-center, non-randomized, single-cohort, post-market clinical follow-up study to confirm the safety, performance, and clinical benefits for the use of the RibFix Titan™ system implants and instrumentation) in the fusion, stabilization, and fixation of fractures in the chest wall including rib reconstructive surgical procedures, trauma, or planned osteotomies.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Indianapolis, Indiana, 46260, United States
Location status: Recruiting
Jamie Williams
CONTACT
Lewis Jacobson, MD
SUB_INVESTIGATOR
Nakul Valsangkar, MD
PRINCIPAL_INVESTIGATOR
Consecutive patients who meet all of the inclusion criteria and none of the exclusion criteria will be eligible for participation in the study, and will be pre-screened for participation in the informed consent process.
The primary objective is the assessment of safety by analyzing reoperation rates related to the RibFix Titan™ at 90 days post-implantation. A reoperation will be considered any additional surgical procedure to revise, adjust, or replace the subject device's components and/or any surgical procedure to manage complications directly caused by the device.
This study is designed to evaluate safety parameters by recording the incidence and frequency of complications and adverse events. Relationship of the events to the implant, instrumentation, and/or procedure through the operative and post-operative follow-up periods shall be specified.
The secondary objectives include functional performance and clinical benefits by clinical evaluation of fracture/osteotomy union and patient reported outcome measures (PROMs). This study will also measure resource utilization in subjects with RibFix Titan™, including intensive care unit (ICU) length of stay, hospital length of stay, and operative time.
Data collection will occur at the following intervals: Pre-operative, Operative, 14-days, 45-days, 90-days, and 1-year post-operatively. Enrollment for the study is anticipated to last approximately 12 months. Allowing for 12 months of follow-up, the total estimated study time to final-patient final-visit will be approximately 24 months.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Rib Fixation
Time frame: 90 days
Assessment of safety by analyzing reoperation rates related to the RibFix Titan™ at 90 days post-implantation. A reoperation will be considered any additional surgical procedure to revise, adjust, or replace the subject device's components and/or any surgical procedure to manage complications directly caused by the device.
Time frame: 12 Months
8-item questionnaire, completed by the patient, with questions asking the patient to rate how much pain has impacted daily functioning over the past 7 days.
Time frame: 12 Months
10-item questionnaire, answered by the patient, with questions asking the patient to rate their level of difficulty performing physical activities.
Time frame: 12 Months
1-item questionnaire asking the patient to rate their pain on average on a numeric scale, from 0 to 10 where 0 is No Pain and 10 is Worst Imaginable Pain.
Contact information is provided by the study sponsor or research team.
Zimmer Biomet
Industry
Zimmer Biomet Patient Outcomes and Experience After Chest Wall Repair With RibFix Titan™
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06069154
Fractures, Bone, Rib Fracture
La Jolla, California, United States
View Trial DetailsNCT07706036
Agnosia, Fractures, Bone
Ankara, Çankaya, Turkey (Türkiye)
View Trial DetailsNCT06757803
Fractures, Bone, Rib Fracture
Asyut, Egypt
View Trial DetailsNCT07553208
Fractures, Bone, Neurologic Manifestations
Antalya, Turkey (Türkiye)
View Trial Details